AU2002339230A1 - A susceptibility gene for late-onset idiopathic parkinson's disease - Google Patents

A susceptibility gene for late-onset idiopathic parkinson's disease

Info

Publication number
AU2002339230A1
AU2002339230A1 AU2002339230A AU2002339230A AU2002339230A1 AU 2002339230 A1 AU2002339230 A1 AU 2002339230A1 AU 2002339230 A AU2002339230 A AU 2002339230A AU 2002339230 A AU2002339230 A AU 2002339230A AU 2002339230 A1 AU2002339230 A1 AU 2002339230A1
Authority
AU
Australia
Prior art keywords
late
disease
susceptibility gene
idiopathic parkinson
onset idiopathic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002339230A
Inventor
Andrew A. Hicks
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
deCode Genetics EHF
Original Assignee
deCode Genetics EHF
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US36322002P priority Critical
Priority to US60/363,220 priority
Application filed by deCode Genetics EHF filed Critical deCode Genetics EHF
Priority to PCT/IB2002/004276 priority patent/WO2003076658A2/en
Publication of AU2002339230A1 publication Critical patent/AU2002339230A1/en
Application status is Abandoned legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/172Haplotypes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2835Movement disorders, e.g. Parkinson, Huntington, Tourette
AU2002339230A 2002-03-08 2002-10-14 A susceptibility gene for late-onset idiopathic parkinson's disease Abandoned AU2002339230A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US36322002P true 2002-03-08 2002-03-08
US60/363,220 2002-03-08
PCT/IB2002/004276 WO2003076658A2 (en) 2002-03-08 2002-10-14 A susceptibility gene for late-onset idiopathic parkinson's disease

Publications (1)

Publication Number Publication Date
AU2002339230A1 true AU2002339230A1 (en) 2003-09-22

Family

ID=27805269

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002339230A Abandoned AU2002339230A1 (en) 2002-03-08 2002-10-14 A susceptibility gene for late-onset idiopathic parkinson's disease

Country Status (2)

Country Link
AU (1) AU2002339230A1 (en)
WO (1) WO2003076658A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10361258A1 (en) 2003-12-24 2005-07-28 Schwarz Pharma Ag Use of substituted 2-aminotetralines for the preventive treatment of Parkinson's disease
DE102004014841B4 (en) 2004-03-24 2006-07-06 Schwarz Pharma Ag Use of rotigotine in the treatment and prevention of Parkinson's plus syndrome
CN103175972B (en) * 2005-10-21 2015-05-20 株式会社芳珂 Atopic dermatitis marker and technique of using the same
MD20140130A2 (en) 2012-06-29 2015-04-30 Pfizer Inc. Novel 4-(substituted-amino)-7H-pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors
EP3083618B1 (en) 2013-12-17 2018-02-21 Pfizer Inc Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
MX2018003215A (en) 2015-09-14 2018-06-08 Pfizer Novel imidazo [4,5-c] quinoline and imidazo [4,5-c][1,5] naphthyridine derivatives as lrrk2 inhibitors.
CR20180592A (en) 2016-06-16 2019-03-05 Denali Therapeutics Inc Pyrimidin-2-ylamino-1H-pyrazoles as inhibitors of LRRK2 for use in the treatment of neurodegenerative disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2402735A1 (en) * 2000-03-13 2001-10-04 Incyte Genomics, Inc. Human transcription factors
WO2001092576A1 (en) * 2000-05-26 2001-12-06 Duke University Methods of screening for parkinson's disease

Also Published As

Publication number Publication date
WO2003076658A2 (en) 2003-09-18
WO2003076658A3 (en) 2003-12-31

Similar Documents

Publication Publication Date Title
TWI324623B (en) Silica-rubber mixtures having improved hardness
TWI331172B (en) Incubator
GB2409485B (en) Mono-trip well completion
IL174990D0 (en) Compounds having crth2 antagonist activity
AU2003272033A1 (en) Flexible display
AU2003290078A1 (en) Sowing machine
AU2003280324A1 (en) Pharmaceutical allergen product
AU2003295539A1 (en) Allele-targeted rna interference
AU2003302463A1 (en) Methods for analyzing a nucleic acid
AU2003225734A1 (en) Efficient retail item assortment
AU2003230762A1 (en) Chloral-free dca in oligonucleotide synthesis
AU2003291579A1 (en) Yield improvement
AU2003285895A1 (en) Measuring a neurological event using clustering
HK1090033A1 (en) Benzoazolypiperazine derivatives having vr1 antagonist activity
GB0210568D0 (en) Display
GB0209812D0 (en) Genetic testing
AU2003231509A1 (en) Compound exhibiting pgd 2 receptor antagonism
SI1620118T1 (en) Reversible pegylated drugs
AU2003251143A1 (en) Probe or stylus orientation
AU2003266947A1 (en) A hydrogel
AU2003275075A1 (en) Compstatin analogs with improved activity
GB0218968D0 (en) Bluetooth serial adapters
GB0405884D0 (en) Modified nucleotides
EP1660017A4 (en) Amino acid prodrugs
AP200603750A0 (en) Corn event MIR 604

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase